Anavex2-73    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病3
156レット症候群4

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04575259October 10, 201929/9/2020OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001Parkinson Disease DementiaDrug: ANAVEX2-73Anavex Life Sciences Corp.Anavex Australia Pty Ltd.;Anavex Germany GmbHRecruiting50 Years85 YearsAll120Phase 2Australia;Spain
2NCT03774459July 9, 20188/12/2018ANAVEX2-73 Study in Parkinson's Disease DementiaA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With DementiaParkinsons Disease With DementiaDrug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsuleAnavex Life Sciences Corp.Anavex Germany GmbHCompleted50 Years85 YearsAll132Phase 2Australia;Spain
3EUCTR2017-004335-36-ES04/07/201811/04/2018A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. - A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: ANAVEX2-73
INN or Proposed INN: ANAVEX2-73
Product Name: ANAVEX2-73
INN or Proposed INN: ANAVEX2-73
Anavex Life Sciences Corp.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 2Spain

156. レット症候群 [臨床試験数:36,薬物数:49(DrugBank:19),標的遺伝子数:77,標的パスウェイ数:112
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 36 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04304482July 1, 20208/3/2020ANAVEX2-73 Study in Pediatric Patients With Rett SyndromeA Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett SyndromeRett SyndromeDrug: ANAVEX2-73 oral liquid;Drug: Placebo oral liquidAnavex Life Sciences Corp.Anavex Australia Pty Ltd.;Anavex Germany GmbHRecruiting5 Years18 YearsFemale69Phase 2/Phase 3Australia
2EUCTR2019-004345-32-GB26/05/202007/02/2020The use of ANAVEX2-73 as a new therapeutic treatment for Patients with Rett SyndromeA Double-Blind, Randomised, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients with Rett Syndrome - The Safety and Efficacy of ANAVEX2-73 in Patients with Rett Syndrome Rett Syndrome
MedDRA version: 20.0Level: PTClassification code 10077709Term: Rett syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: ANAVEX2-73
INN or Proposed INN: ANAVEX2-73 (blarcamesine)
Other descriptive name: ANA001XHCl (Syntagon) or VEXA-04 (Patheon)
Anavex Germany GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
30Phase 2Australia;United Kingdom
3NCT03941444May 6, 20196/5/2019ANAVEX2-73 Study in Patients With Rett SyndromeA Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett SyndromeRett SyndromeDrug: ANAVEX2-73;Drug: PlacebosAnavex Life Sciences Corp.NULLRecruiting18 Years45 YearsFemale30Phase 2Australia;United Kingdom
4NCT03758924February 28, 201925/11/2018Study of ANAVEX2-73 in Patients With Rett SyndromeA Double-Blind, Randomized, Placebo-Controlled, Dose Titration Study of ANAVEX2-73 in Patients With Rett SyndromeRett SyndromeDrug: ANAVEX2-73;Drug: PlaceboAnavex Life Sciences Corp.International Rett Syndrome Foundation Rettsyndrome.orgActive, not recruiting18 Years45 YearsFemale31Phase 2United States